Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Calvin Yeang, Ewa Karwatowska‐Prokopczuk, Fei Su, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 11, pp. 1035-1046
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, et al.
Nature Reviews Cardiology (2023) Vol. 20, Iss. 12, pp. 845-869
Open Access | Times Cited: 128
From target discovery to clinical drug development with human genetics
Katerina Trajanoska, Claude Bhérer, Daniel Taliun, et al.
Nature (2023) Vol. 620, Iss. 7975, pp. 737-745
Closed Access | Times Cited: 98
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
Waqas Malick, Sascha N. Goonewardena, Wolfgang Köenig, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 16, pp. 1633-1645
Open Access | Times Cited: 46
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives
Pierandrea Vinci, Filippo Giorgio Di Girolamo, Emiliano Panizon, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 18, pp. 6721-6721
Open Access | Times Cited: 41
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 32
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity
David M. Leistner, Andrés Laguna‐Fernandez, Arash Haghikia, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 7, pp. 856-865
Open Access | Times Cited: 17
Recent advances in demystifying the metabolism of lipoprotein(a)
Kévin Chemello, Dick C. Chan, Gilles Lambert, et al.
Atherosclerosis (2022) Vol. 349, pp. 82-91
Open Access | Times Cited: 42
Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
Bożena Sosnowska, Stanisław Surma, Maciej Banach
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1573-1573
Open Access | Times Cited: 40
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease
Om P Ganda
Current Opinion in Lipidology (2023) Vol. 34, Iss. 3, pp. 105-113
Closed Access | Times Cited: 28
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering
Michelle L. O’Donoghue, Robert S. Rosenson, J. Antonio G. López, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 9, pp. 790-797
Open Access | Times Cited: 14
Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
Henriette Thau, Sebastian Neuber, Maximilian Y. Emmert, et al.
Cardiology and Therapy (2024) Vol. 13, Iss. 1, pp. 39-67
Open Access | Times Cited: 12
The future of valvular heart disease assessment and therapy
Partho P. Sengupta, Jolanda Kluin, Seung‐Pyo Lee, et al.
The Lancet (2024) Vol. 403, Iss. 10436, pp. 1590-1602
Open Access | Times Cited: 9
Current RNA strategies in treating cardiovascular diseases
Shirley Pei Shan Chia, Jeremy Kah Sheng Pang, Boon-Seng Soh
Molecular Therapy (2024) Vol. 32, Iss. 3, pp. 580-608
Open Access | Times Cited: 8
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table
François Mach, Frank L.J. Visseren, Nilo B. Cater, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 5, pp. e685-e700
Closed Access | Times Cited: 8
Exosomes and non-coding RNAs: Exploring their roles in human myocardial dysfunction
Magdalena Kulus, Maryam Farzaneh, Mohadeseh Sheykhi-Sabzehpoush, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117853-117853
Closed Access | Times Cited: 1
Advancing targeted protein degradation for metabolic diseases therapy
Qianqian Zhou, Haitao Xiao, Fan Yang, et al.
Pharmacological Research (2022) Vol. 188, pp. 106627-106627
Open Access | Times Cited: 34
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
Berit Storgaard Hedegaard, Christian Sørensen Bork, Morten Kaltoft, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 21, pp. 1998-2010
Open Access | Times Cited: 33
New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Iveta Merćep, Dominik Strikić, Ana Marija Slišković, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 839-839
Open Access | Times Cited: 29
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Umidakhon Makhmudova, Elisabeth Steinhagen‐Thiessen, Massimo Volpe, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 10, pp. 1107-1125
Open Access | Times Cited: 7
Lp(a): a New Pathway to Target?
Nick S. Nurmohamed, Jordan M. Kraaijenhof, Erik S.G. Stroes
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 11, pp. 831-838
Open Access | Times Cited: 25
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Constantine E. Kosmas, Maria D. Bousvarou, E Papakonstantinou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13622-13622
Open Access | Times Cited: 15
Particle Number and Characteristics of Lipoprotein(a), LDL, and apoB
Sotirios Tsimikas, Vera Bittner
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 3, pp. 396-400
Open Access | Times Cited: 5
Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study
Stephanie Wissel, Hubert Scharnagl, Marcus E. Kleber, et al.
Clinical Research in Cardiology (2025)
Closed Access
Association of rs3798220 Polymorphism with Cardiovascular Incidents in Individuals with Elevated Lp(a)
Dunja Leskovar, Livija Šimičević, Lana Ganoci, et al.
Diagnostics (2025) Vol. 15, Iss. 4, pp. 404-404
Open Access
Cutting-edge stroke prevention strategies
Lisa Kaindl, Julian Frederic Hotz, Julia Ferrari
eNeurologicalSci (2025) Vol. 39, pp. 100561-100561
Open Access
Page 1 - Next Page

Scroll to top